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E-mail address: h.stunnenberg@ncmls.ru.nl (H.G. SAcute myeloid leukemia (AML) associated translocations often cause gene fusions that encode onco-
fusion proteins. Although many of the breakpoints involved in chromosomal translocations have
been cloned, in most cases the role of the chimeric proteins in tumorigenesis is not elucidated. Here
we will discuss the fusion proteins of the 4 most common translocations associated with AML as
well as the common molecular mechanisms that these four and other fusion proteins utilize to
transform progenitor cells. Intriguingly, although the individual partners within the fusion proteins
represent a wide variety of cellular functions, at the molecular level many commodities can be
found.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Acute myeloid leukemia
Acute myeloid leukemia (AML) is a quickly progressive malig-
nant disease in which there are too many immature blood-forming
cells accumulating in the bone marrow and interfering with the
production of normal blood cells. AML is the most common acute
leukemia affecting adults, and its incidence increases with age
[1]. With approximately 1% of cancer deaths worldwide AML is a
relatively rare disease. Still, its incidence is expected to increase
as the population ages. The symptoms of AML are caused by
replacement of normal bone marrow with leukemic cells, resulting
in a drop in red blood cells, platelets, and normal white blood cells.
The early signs of AML include fever, weakness and fatigue, loss of
weight and appetite, and aches and pains in the bones or joints.
Other signs of AML include tiny red spots in the skin, easy bruising
and bleeding, frequent minor infections, and poor healing of minor
cuts. As an acute leukemia, AML progresses rapidly and is typically
fatal within weeks or months if left untreated. However, acute
myeloid leukemia is a potentially curable disease, although only
a minority of patients are cured with current therapies.
The majority of cases of AML are associated with non-random
chromosomal translocations [2] that often result in gene rear-
rangements. A wide variety of different studies have provided evi-
dence for the central role of gene rearrangements in the initiation
of leukemia. The most important ones showed that gene rearrange-
ments closely correlate with speciﬁc tumor phenotypes, that suc-
cessful treatment is paralleled by a decrease or eradication of thechemical Societies. Published by E
tunnenberg).disease associated chimera, that gene fusion constructs in animal
models give rise to similar disorders as those seen in human neo-
plasms that carry the same chimera and that silencing fusion tran-
scripts in vitro leads to the reversal of leukemogenesis, decreased
proliferation and/or differentiation [3].
Many of the gene rearrangements involve a locus encoding a
transcriptional activator, leading to expression of a fusion protein
that retains the DNA-binding motifs of the wild-type protein.
Moreover, in many instances the fusion partner is a transcriptional
protein that is capable of interacting with a corepressor complex.
A commonly accepted paradigm is that through aberrant recruit-
ment of a corepressor to a locus of active transcription, the fusion
protein alters expression of target genes necessary for myeloid
development, thus laying the groundwork for leukemic transfor-
mation [4]. Potential targeting of this interaction has become a
major focus for development of novel therapeutics. ATRA serves
as a prototype: by altering corepressor interaction with the acute
promyelocytic leukemia (APL) fusion protein, ATRA effectively in-
duces remission and has become a mainstay of treatment of this
previously fatal disease [5]. However, to date, APL represents both
the most curable as the best studied subtype of AML, while molec-
ular data on other fusion proteins is limited or absent. Still, the
work on PML-RARa has inspired the molecular analysis of many
other AML-associated oncofusion proteins, especially AML1-ETO,
CBFb-MYH11 and MLL-fusions. Together with the analysis on
some less well characterized oncofusion proteins, these studies
are beginning to uncover not only the unique aspects of the vari-
ous oncofusion proteins but also allow a more thorough under-
standing of the common molecular plateau that is used to
transform cells.lsevier B.V. All rights reserved.
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To date, a total of 749 recurrent balanced aberrations have been
identiﬁed in AML [6]. In Table 1 representatives of recurrent bal-
anced aberrations and their corresponding fusion genes are listed.
The frequencies of the four most common translocations are be-
tween 3% and 10% while for others the prevalence is signiﬁcantly
smaller. Here we will ﬁrst discuss the four most prevalent oncofu-
sion proteins: PML-RARa, AML1-ETO, CBFb-MYH11 and MLL-fu-
sions after which we will discuss the common molecular
characteristics of these and other AML related oncofusion proteins.
3. Common AML-associated translocations
3.1. t(15;17), PML-RARa
The t(15;17) translocation is found in approximately 95% of
acute promyelocytic leukemias (APLs), a speciﬁc subtype of AML.
The translocation results in the expression of the PML-RARa onco-
fusion gene in hematopoietic myeloid cells [7,8]. The PML-RARa
oncofusion protein acts as a transcriptional repressor that inter-
feres with gene expression programs involved in differentiation,
apoptosis and self-renewal [9].
At the molecular level PML-RARa behaves as an aberrant RAR.
In absence of all-trans retinoic acid (ATRA), RARa interacts with
RXR, itself a nuclear receptor, and binds to DNA. The normal
RARa/RXR heterodimer recruits corepressor complexes and re-
presses transcription of its target genes. A conformational change
caused by binding of ATRA at physiological concentrations triggers
the dissociation of the corepressors and promotes the recruitment
of coactivators. In contrast, PML-RARa acts as a constitutive repres-
sor that is insensitive to physiological concentrations of ATRA
[10–12]. Under physiological concentrations of ATRA, PML-RARa
complexes bind RXR and form an oligomeric complex that is essen-
tial for its oncogenic potential as it facilitates binding to widely
spaced direct repeats [13–15] and has been shown to be a critical
determinant for the transforming potential of PML-RARa com-
plexes [16,17]. To overcome the transforming potential of PML-
RARa, human APL patients are treated during the early phase of
the disease with pharmacological doses of ATRA and/or As2O3
[10,18]. This treatment has been shown to degrade PML-RARa
and to dissociate HDACs creating a hyperacetylated chromatin
state [14,19,20].
3.2. t(8;21), AML1-ETO
Approximately 10% of AML cases carry the t(8;21) translocation,
which involves the AML1 (RUNX1) and ETO genes, and express the
resulting AML1-ETO fusion protein. AML1 is a DNA-binding tran-
scription factor crucial for hematopoietic differentiation [21,22]Table 1
AML-associated oncofusion proteins.
Translocation Prognosis FAB
t(8;21) Favorable M2
t(15;17) Favorable M3
inv(16) Favorable M4
der(11q23) Variable M4/M5
t(9;22) Adverse M1/M2
t(6;9) Adverse M2/M4
t(1;22) Intermediate M7
t(8;16) Adverse M4/M5
t(7;11) Intermediate M2/M4
t(12;22) Variable M4/M7
inv(3) Adverse M1/M2/M4/M6
t(16;21) Adverse M1/M2/M4/M5while ETO is a protein harbouring transcriptional repressor activi-
ties [23]. The fusion protein AML1-ETO is suggested to function as
a transcriptional repressor by recruiting NCoR/SMRT/HDAC com-
plexes to DNA through its ETO moiety [23]. Moreover, it has been
shown that AML1-ETO blocks AML1-dependent transactivation in
various promoter reporter assays, suggesting it may function as a
dominant negative regulator of wild-type AML1 [24–26]. AML1-
ETO was recently hypothesized to target DNA through E-box mo-
tifs as a result of physical interactions with transcription factors
of the E-protein family, in particular HEB/TCF12 [27,28].
3.3. Inv(16), CBFb-MYH11
Inv(16) is found in approximately 8% of acute myeloid leukemia
(AML) cases. Inv(16) fuses the ﬁrst 165 amino acids of core binding
factor b (CBFb) to the C-terminal coiled-coil region of a smooth
muscle myosin heavy chain (MYH11) [29]. CBFb interacts with
the AML1 transcription factor to increase the afﬁnity of AML1 for
DNA [30–32] and to stimulate the ability of AML1 to either activate
or repress transcription [33,34]. In contrast, the CBFb-MYH11 fu-
sion protein is suggested to cooperate with AML1 to repress tran-
scription [35]. AML1 binds the mSin3A and Groucho corepressors,
and the inv(16) fusion protein can form a trimeric complex with
AML1 and mSin3A [35]. In addition, the C terminus of the CBFb-
MYH11 fusion protein is required for repression [35], suggesting
that the fusion protein may cooperate with AML1 to recruit core-
pressors. Indeed, the C-terminal MYH11 portion of inv(16) is both
necessary and sufﬁcient for transcriptional repression and is sufﬁ-
cient for association with SIN3A and HDAC8 [36].
3.4. 11q23, MLL rearrangements
MLL is implicated in at least 10% of acute leukemias (AL) of var-
ious types: acute lymphoblastic leukemias (ALL), acute myeloid
leukemias (AML), biphenotypic ALs, treatment related leukemias
and infant leukemias. In general the prognosis is poor for AML pa-
tients harbouring MLL translocations [37]. In these leukemias, the
MLL protein fuses to one of >50 identiﬁed partner genes, resulting
in a MLL-fusion protein that acts as a potent oncogene [38]. The
amino-terminal portion of MLL serves as a targeting unit to direct
MLL oncoprotein complexes to their target loci through DNA-bind-
ing [39,40] whereas the fusion partner portion serves as an effecter
unit that causes sustained transactivation [41]. While extensive
gene expression signatures have been determined for primary hu-
man leukemia samples [42–47], the direct genomic targets of MLL-
fusion proteins in AML remain largely unknown, while only one re-
port described the global role of MLL-AF4 fusion in ALL [48]. Preli-
minary results in ALL suggest that MLL-fusion proteins produce
gross defects in chromatin structure through alteration of the dis-
tribution of histone modiﬁcation associated with the transcriptionOncofusion-protein Occurence
AML1-ETO 10% of AML
PML-RARa 10% of AML
CBFb-MYH11 5% of AML
MLL-fusions 4% of AML
BCR-ABL1 2% of AML
DEK-CAN <1% of AML
OTT-MAL <1% of AML
MOZ-CBP <1% of AML
NUP98-HOXA9 <1% of AML
MN1-TEL <1% of AML
/M7 RPN1-EVI1 <1% of AML
/M7 FUS-ERG <1% of AML
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genes, but whether this is also the case in AML remains elusive.
4. Less prevalent translocations
The remaining balanced aberrations are uncommon; together
constituting 6% of all AML cases. Therefore, in total approximately
35% of AMLs are characterized by translocations. Although the
importance of these gene rearrangements in the onset of leukemo-
genesis is evident, the individual protein partners within the fusion
proteins represent a wide variety of cellular functions. Still, the
gene fusions all result in uncontrolled proliferation of progenitor
cells. Hence, it can be expected that the various oncofusion pro-
teins utilize common molecular mechanisms to transform cells. In-
deed, as discussed below, a close examination at the actions of the
individual oncofusion proteins reveals many commodities at mul-
tiple levels such as transcriptional regulation, cofactor involve-
ment, chromatin modiﬁcation and pathway usage (Fig. 1).
5. Disruption of transcription programs
Disruption of existing transcription proﬁles is a hallmark of
AMLs harbouring chromosomal translocations. This disruption
can happen at multiple levels. The TF itself can be involved in
the translocation or the translocation results in an aberrantly ex-
pressed coactivator. Either way, it is generally assumed that the
resulting fusion protein targets key hematopoietic regulators and
thereby disrupts the normal differentiation program (Fig. 2).
5.1. Aberrant TFs
AML1-ETO is the hallmark example of an aberrantly regulated
transcription factor in AML. AML1 is a DNA-binding transcription
factor required for hematopoiesis [21,22], while ETO is a corepres-
sor molecule [23]. The translocation fuses the N-terminal DNA-
binding domain of AML1 to almost all of ETO resulting in the local-
ization of the transcriptional repressor functions of ETO to AML1
target genes. Another transcription factor, CBFb, interacts with
AML1 to increase the afﬁnity of AML1 for DNA [30–32]. As dis-
cussed above, also this transcription factor can be involved in a
chromosomal translocation and the resulting CBFb-MYH11 fusion
protein is suggested to cooperate with AML1 to repress transcrip-
tion [35].
Another group of translocations fuse the NUP98 protein to sev-
eral homeodomain-containing transcription factors [49]. NUP98-
HOXA9 is the prototype of this group and generally these fusion
proteins are thought to act as aberrant transcription factors that in-
duce proliferation and block differentiation of hematopoietic pre-
cursors [50]. Similar as for NUP98, fusion of the MLL protein with
several partner genes, results in oncofusion proteins that act as po-
tent oncogenes [38]. In these fusions, the amino-terminal portionFig. 1. Common molecular targets of oncofusion proteins.of MLL serves as a targeting unit to direct MLL oncoprotein com-
plexes to their target loci through DNA-binding [39,40] whereas
the fusion partner portion serves as an effecter unit that causes
sustained transactivation of target genes [41]. RPN1-EVI1 repre-
sents a ﬁfth example of transcription factor involvement in oncofu-
sion proteins. Fusion constructs of EVI1 are thought to result in
activation of the expression of EVI1, thereby interfering with the
cellular mechanisms that control EVI1 expression. EVI1 is a nuclear
transcription factor involved in many signaling pathways for both
corepression and coactivation of cell cycle genes. Although the
underlying molecular mechanisms have not been elucidated,
in vitro experiments suggest that EVI1 expression prevents the ter-
minal differentiation of bone marrow progenitor cells to granulo-
cytes and erythroid cells [51].
5.2. Coactivators
Apart from misregulation at the level of DNA-binding transcrip-
tion factors, several AMLs display gene rearrangements that result
in aberrant expression of transcriptional coactivators. For example,
one of the common targets of chromosomal translocations is the
histone acetyltransferase MOZ. MOZ was ﬁrst identiﬁed as a gene
involved in the translocation t(8;16) resulting in the MOZ–CBP fu-
sion gene. The MOZ–p300, MOZ–TIF2 and MOZ–NcoA3 fusion genes
were later identiﬁed in AMLs harboring t(8;22), inv(8) and t(8;20),
respectively [52]. The non-fused MOZ has been shown to modulate
gene transcription through activation of transcription factor com-
plexes [53]. In its turn CBP and p300 are major HATs that function
as coactivators for various transcription factors, while TIF2 (NcoA2/
GRIP1) and NcoA3 (TRAM-1/RAC3/pCIP/AIB-1) are adaptor pro-
teins that combine nuclear receptors with CBP. It has been sug-
gested that the fusion of MOZ with the above proteins alters its
coactivator capacities as compared to the non-fused protein. These
alterations in the coactivation potential of the fused protein have
been hypothesized to be the main mechanism of leukemogenesis
in these AML varieties [52,53].
As MOZ, MN1, which is involved in the t(12;22) translocation,
acts as a transcriptional coactivator [54,55]. t(12;22) fuses almost
all the coding sequence of MN1 to two-thirds of the coding se-
quence of TEL (ETV6). MN1-TEL is thought to act as a novel tran-
scription factor causing transcriptional deregulation of genes
normally repressed by TEL [56]. In addition, through its MN1 moi-
ety, MN1-TEL has been shown to repress RARa/RXR-mediated
transcription [57].
Finally, MAL, one of the fusion partners in the OTT-MAL oncofu-
sion protein, has been described as a potent transcriptional coacti-
vator of the myocardin-related transcription factor (MRTF) family,
which is implicated in gene expression by serum response factor
(SRF) [58]. Again fusion of the transcription coactivator alters its
normal function and is suggested to result in the constitutive acti-
vation of SRF target gene expression [59,60].
5.3. Hematopoietic master regulators
Aberrant regulation of proteins that determine hematopoietic
cell fates is central to the onset of AML. Indeed, many of the above
described fusion proteins are directly involved in altering the tran-
scriptional program of key regulators of hematopoiesis. The best
example is the t(8;21) chromosomal aberrations affecting the key
hematopoietic regulator AML1, while the CBFb-MYH11 oncofusion
protein can be expected to exert similar effects on the hematopoi-
etic differentiation programs regulated by AML1, due to its interac-
tion with this protein [30–32]. Similarly, MOZ has been shown to
modulate gene transcription through activation of the AML1 and
SPI1 transcription factor complexes. Therefore, inhibition of key
hematopoietic regulator mediated transcription by MOZ-fusion
Fig. 2. Overview of DNA-binding oncofusion proteins.
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kemogenesis in this AML variety [52,53].
Apart from aberrant regulation of the key hematopoietic master
regulator protein itself, oncofusion proteins might also affect these
proteins through regulation of their expression. This is exempliﬁed
by the recent analysis of genome-wide binding sites of PML-RARa
[14] that suggested regulation of several key hematopoietic master
regulator genes, such as GFI1, AML1 and SPI1 (Fig. 3) by this protein.
6. Nuclear receptor signalling
Nuclear receptors are key regulators of cell growth and differen-
tiation, homeostasis and development and represent a large family
of ligand-dependent transcription factors [61]. In addition, nuclear
receptors represent key targets for treatment, exempliﬁed by the
great number of studies dedicated to examining the effects of nu-
clear receptor ligands on cancer cells. The hallmark nuclear recep-
tor associated with AML is RARa which is directly misregulated
through chromosome translocations involving chromosome 17. In-
deed RARa-fusions such as PML-RARa and PLZF-RARa are hall-
mark proteins of AML FAB M3. Apart from affecting RARa these
translocation also target RXR, another nuclear receptor, through di-
rect interaction with this protein [14,16,17]. RARa has also been
suggested to interact with AML1-ETO in regulating expression of
the RARb gene [62], although it is currently unclear whether this
interplay can be extended to other RARa regulated genes. In addi-
tion, recent ﬁndings indicate that another oncofusion protein,MN1-TEL, represses RARa/RXR-mediated transcription through
its MN1 moiety [57]. Together these results identify the retinoic
acid signalling pathway as a major target of oncofusion proteins.
In addition to the nuclear receptor RAR, it is not unlikely that
oncofusion proteins might also aberrantly regulate other nuclear
receptors. Indeed, it has been suggested that CAN (NUP214), one
of the fusion partners of DEK-CAN interacts and modulates the
function of the vitamin D receptor (VDR) [63], thereby implying
a role for DEK-CAN in disturbing VDR regulated pathways.
7. Structural organisation
Often one of the partners in oncofusion proteins represent a
structural protein. Examples of these include the PML body associ-
ated PML protein in PML-RARa, and the nuclear pore complex pro-
teins NUP214 (CAN) and NUP98 in DEK-CAN and NUP98-HOXA9,
respectively. At the molecular level these structural components
are suggested to be vital for the oligomerization properties of these
oncofusion proteins. In this case oligomerization is suggested to in-
duce an altered interaction with transcriptional coregulators and
thereby representing an alternative mechanism of oncogenic acti-
vation [64]. Another possibility is that the fusion disrupts the ori-
ginal structure that contained the non-fused protein. This is
exempliﬁed by the disruption of PML bodies in PML-RARa express-
ing APL cells. Similarly, expression of the nucleoporin-fusion pro-
teins might result in alteration in nuclear pore complexes and in
aberrant nucleocytoplasmic transport. An intriguing possibility is
Fig. 3. PML-RARa and RXR colocalization to genomic regions in NB4 cells. Overview of the AML1 (RUNX1), GFI1 and SPI1 PML-RARa/RXR binding sites. In red PML ChIP-seq
data is plotted, in purple RARa data.
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the morphology of the cell. Oncofusion proteins are associated
with different FAB types (Table 1), i.e. different morphologies.
Although these can be due to the differentiation step in which
the fusion gene functions or the oncofusion protein induced gene
program, the structural aberration might also be a consequence
of the gene fusion itself.
8. ETS factors
The SPI1 (PU.1) gene encodes an ETS-domain transcription fac-
tor that is a master regulator of gene expression during myeloid
cell development. SPI1 has recently been identiﬁed both as a part-
ner within the PML-RARa complex [65] as well as a factor that is
regulated at the transcriptional level by the PML-RARa protein it-
self [14]. Moreover, SPI1 was identiﬁed as a downstream target
of AML1 [66], opening the possibility that it is also transcription-
ally regulated by AML1-ETO in t(8;21) cells. In addition to SPI1,
other ETS factors, such as TEL and ERG have been associated with
AML. TEL is directly targeted in a gene rearrangement with MN1
while ERG has been identiﬁed in a chromosomal translocation
involving FUS. While the molecular mechanisms of FUS-ERG med-
iated transformation are unknown, MN1-TEL is thought to act as a
novel transcription factor causing transcription deregulation of
genes normally repressed by TEL [56]. Moreover, as TEL normally
binds FLI1, aberrant regulation of FLI1 might also be involved in
causing the proliferative state in the MN1-TEL expressing AMLs.
Together with SPI1, these examples suggest an important role of
ETS factors in leukemogenesis.9. Epigenetics
9.1. Acetylation
Throughout the years many studies have been dedicated to the
identiﬁcation of epigenetic modiﬁcations associated with oncofu-
sion protein binding. This work was largely inspired by PML-RARa
which was the ﬁrst protein complex in which, with the identiﬁca-
tion of HDAC association, an epigenetic factor was found. These
studies were later followed by suggestions of PML-RARa mediated
recruitment of DNMTs, EZH2 and SUV39H and the subsequent
establishment of a repressive chromatin environment with low
acetylation, high DNA methylation, high H3K27me3 and high
H3K9me3 at PML-RARa binding sites. However, these studies were
largely focussed on the promoter of the RARb gene and a global
analysis showed that for most PML-RARa target sites many of
the previous suggested epigenetic modiﬁcations were not present
and that essentially only HDACs were recruited [14], for example
to the CCL2 gene (Fig. 4). Analysis of other AML-associated oncofu-
sion proteins seem to conﬁrm the intimate connection between
these proteins and the acetylome. AML1-ETO is suggested to func-
tion as a transcriptional repressor by recruiting NCoR/SMRT/HDAC
complexes to DNA through its ETO moiety [23], while the tran-
scriptional repression mechanisms of the CBFb-MYH11 fusion pro-
tein are also suggested to be mediated through cooperation of the
fusion protein with AML1 and recruitment of HDAC containing
corepressor complexes [35]. Changes in the acetylome can also
be expected in AMLs that harbour translocations that affect partic-
ular coactivator proteins. The hallmark examples of these include
Fig. 4. ATRA induces epigenetic changes at the CCL2 PML-RARa/RXR binding region in NB4 cells. In red the PML, in purple the RARa and in blue the RXR ChIP-seq data is
plotted for proliferating and 24 h ATRA treated NB4 cells. For H3K9K14ac (pink), H3K27me3 (yellow), H3K9me3 (green) and DNAme (turquoise) the data is plotted both for
proliferating and for 24 h (H3K9K14ac and H3K27me3) or 48 h (DNAme) ATRA treated NB4 cells.
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cation t(8;16) fuses MOZ and CBP genes while t(8;22) fuses MOZ
and p300, all three encoding proteins with histone acetyltransfer-
ase activity [52]. Similarly, the OTT coactivator which is part of the
fusion OTT-MAL, contains a highly conserved SPOC domain which
is suggested to interact with SMRT and NCoR corepressor com-
plexes and thereby recruit HDAC activities [60].
9.2. Other chromatin alterations
Apart from changes in the acetylome, numerous other chroma-
tin changes have been suggested to be associated with speciﬁc
oncofusion proteins. For example, MLL-fusions have been de-
scribed to result in aberrant recruitment of enzymes that canmediate histone H3 lysine 4 and 79 methylation [48,67] and these
two chromatin marks are therefore expected to be hallmarks of the
MLL-fusion epigenome. Chromatin organisation is also likely to be
affected in the AML subtypes harboring the t(11;20) or the t(6;9)
translocation that express the NUP98-TOP1 and DEK-CAN oncofu-
sion proteins, respectively, as both Topoisomerase 1 (TOP1) and
DEK have been recognized for their key roles in relaxing super-
coiled DNA [68,69]. Moreover, a recent study identiﬁed DEK as a
histone chaperone [70]. Therefore, aberrant regulation of these
two proteins can be expected to have a signiﬁcant impact on chro-
matin integrity.
For DNA methylation, PML-RARa mediated recruitment of DNA
methyltransferases to the RARb promoter has long been used as
the prime example of the interplay between oncogenes and this
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the recruitment of DNA methyltransferases to all PML-RARa bind-
ing sites [14]. Still, recent large-scale DNAmethylation proﬁling re-
vealed the existence of distinct DNA methylation patterns in AML
and identiﬁed novel, biologically and clinically relevant deﬁned
AML subgroups [71]. These ﬁndings suggest that although some
epigenetic alterations might not be directly related to oncofusion
protein binding, the indirectly induced epigenetic state might still
be highly correlative with the expressed fusion gene.
10. Pathways
In many instances one of the partners in a gene rearrangement
codes for a transcriptional protein. As a consequence, AML-associ-
ated fusion proteins often function as aberrant transcriptional reg-
ulators. The resulting expression proﬁles can vary signiﬁcantly and
can even be used to classify AMLs harboring different gene rear-
rangements [72]. Despite these variations in gene expression all
AML-associated fusion proteins interfere with the process of mye-
loid differentiation, suggesting that ultimately their unique molec-
ular properties converge into common molecular mechanisms to
transform cells. A plausible explanation on how this can be
achieved would be that ultimately similar pathways are affected
by the fusion proteins. Therefore it is essential to elucidate the
downstream pathways and biological processes where oncofusion
protein-regulated genes are contributing. However, thus far these
analysis have been limited and only one study tried to identify
the common pathways of several oncofusion proteins [73]. This
transcription analysis of AML1-ETO, PML-RARa and PLZF-RARa
expressing cells revealed aberrant regulation of pathways involved
in signaling, apoptosis and cell structure. Other, non-comparative,
studies involving single oncofusion proteins seem to conﬁrm the
role of these proteins in signaling and apoptosis. For example
BCR-ABL activates the Ras signal transduction pathway via it’s link-
age to son-of-sevenless (SOS), a Ras activator and has been shown
to inhibit apoptosis. Similarly, EVI1, a fusion partner in RPN1-EVI1,
has been shown to be involved in the downstream signaling path-
way of transforming growth factor beta (TGF-b) and in inhibiting
JNK dependent activation of key transcription factors for the apop-
totic response. Still, it remains to be determined whether the apop-
totic and the various signaling pathways are also targets of other
oncofusion proteins.
11. Outlook
Although many of the breakpoints involved in speciﬁc chro-
mosomal translocations have been cloned and novel ones are
still being discovered, in most cases the molecular mechanisms
and the central players leading to tumorigenesis are not eluci-
dated. Often, the chromosomal translocation leads to the expres-
sion of fusion genes that encode chimeric proteins that can drive
oncogenic transformation. It is becoming exceedingly clear that a
detailed knowledge of the molecular pathways inﬂuenced by the
expression of these oncofusion proteins has an enormous poten-
tial and will lay the basis for diagnosis, prognosis and drug ther-
apy development. However, the progress in elucidating the
actions of oncofusion proteins has been hampered by the lack
of tools to perform a comprehensive analysis. This limitation
has recently been overcome by the development of several
high-throughput DNA sequencing techniques that allow large-
scale identiﬁcation of chromosomal aberrations, gene fusions,
(oncofusion) protein binding, gene expression and epigenetic
modiﬁcations. Therefore, it is now within our reach to perform
a detailed characterization of the genomic targets of oncofusion
protein as well as the effects of these proteins on gene transcrip-tion and the epigenetic state. Apart from providing novel in-
sights into the etiology of cancer, a detailed understanding of
the general mechanisms associated with cancer onset is likely
to provide a rationale for therapy design and epigenetic bio-
marker development.
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